TILs have been harnessed in adoptive cell therapy, a form of immunotherapy where TILs are isolated from a patient's tumor, expanded in the laboratory, and then re-infused into the patient. This approach has shown promise, particularly in treating melanoma, where it has led to significant tumor regression in some patients. However, the effectiveness of TIL-based therapies can vary based on tumor type and individual patient factors.
